Cargando…
KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy
Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angi...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827133/ https://www.ncbi.nlm.nih.gov/pubmed/31600989 http://dx.doi.org/10.3390/cancers11101514 |
_version_ | 1783465250208612352 |
---|---|
author | Ghimessy, Áron Kristof Gellert, Áron Schlegl, Erzsebet Hegedus, Balazs Raso, Erzsebet Barbai, Tamas Timar, Jozsef Ostoros, Gyula Megyesfalvi, Zsolt Gieszer, Balazs Moldvay, Judit Renyi-Vamos, Ferenc Lohinai, Zoltan Hoda, Mir Alireza Klikovits, Thomas Klepetko, Walter Laszlo, Viktoria Dome, Balazs |
author_facet | Ghimessy, Áron Kristof Gellert, Áron Schlegl, Erzsebet Hegedus, Balazs Raso, Erzsebet Barbai, Tamas Timar, Jozsef Ostoros, Gyula Megyesfalvi, Zsolt Gieszer, Balazs Moldvay, Judit Renyi-Vamos, Ferenc Lohinai, Zoltan Hoda, Mir Alireza Klikovits, Thomas Klepetko, Walter Laszlo, Viktoria Dome, Balazs |
author_sort | Ghimessy, Áron Kristof |
collection | PubMed |
description | Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angiogenesis has been well established, its prognostic and predictive role in the above setting remains unclear. The association between KRAS exon 2 mutational status and clinicopathological variables including progression-free survival and overall survival (PFS and OS, respectively) was retrospectively analyzed in 501 Caucasian stage IIIB-IV LADC patients receiving first-line platinum-based chemotherapy (CHT) with or without bevacizumab (BEV). EGFR (epidermal growth factor receptor)-mutant cases were excluded. Of 247 BEV/CHT and 254 CHT patients, 95 (38.5%) and 75 (29.5%) had mutations in KRAS, respectively. KRAS mutation was associated with smoking (p = 0.008) and female gender (p = 0.002) in the BEV/CHT group. We found no difference in OS between patients with KRAS-mutant versus KRAS wild-type tumors in the CHT-alone group (p = 0.6771). Notably, patients with KRAS-mutant tumors demonstrated significantly shorter PFS (p = 0.0255) and OS (p = 0.0186) in response to BEV/CHT compared to KRAS wild-type patients. KRAS mutation was an independent predictor of shorter PFS (hazard ratio, 0.597; p = 0.011) and OS (hazard ratio, 0.645; p = 0.012) in the BEV/CHT group. G12D KRAS-mutant patients receiving BEV/CHT showed significantly shorter PFS (3.7 months versus 8.27 months in the G12/13x group; p = 0.0032) and OS (7.2 months versus 16.1 months in the G12/13x group; p = 0.0144). In this single-center, retrospective study, KRAS-mutant LADC patients receiving BEV/CHT treatment exhibited inferior PFS and OS compared to those with KRAS wild-type advanced LADC. G12D mutations may define a subset of KRAS-mutant LADC patients unsuitable for antiangiogenic therapy with BEV. |
format | Online Article Text |
id | pubmed-6827133 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-68271332019-11-18 KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy Ghimessy, Áron Kristof Gellert, Áron Schlegl, Erzsebet Hegedus, Balazs Raso, Erzsebet Barbai, Tamas Timar, Jozsef Ostoros, Gyula Megyesfalvi, Zsolt Gieszer, Balazs Moldvay, Judit Renyi-Vamos, Ferenc Lohinai, Zoltan Hoda, Mir Alireza Klikovits, Thomas Klepetko, Walter Laszlo, Viktoria Dome, Balazs Cancers (Basel) Article Bevacizumab, combined with platinum-based chemotherapy, has been widely used in the treatment of advanced-stage lung adenocarcinoma (LADC). Although KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutation is the most common genetic alteration in human LADC and its role in promoting angiogenesis has been well established, its prognostic and predictive role in the above setting remains unclear. The association between KRAS exon 2 mutational status and clinicopathological variables including progression-free survival and overall survival (PFS and OS, respectively) was retrospectively analyzed in 501 Caucasian stage IIIB-IV LADC patients receiving first-line platinum-based chemotherapy (CHT) with or without bevacizumab (BEV). EGFR (epidermal growth factor receptor)-mutant cases were excluded. Of 247 BEV/CHT and 254 CHT patients, 95 (38.5%) and 75 (29.5%) had mutations in KRAS, respectively. KRAS mutation was associated with smoking (p = 0.008) and female gender (p = 0.002) in the BEV/CHT group. We found no difference in OS between patients with KRAS-mutant versus KRAS wild-type tumors in the CHT-alone group (p = 0.6771). Notably, patients with KRAS-mutant tumors demonstrated significantly shorter PFS (p = 0.0255) and OS (p = 0.0186) in response to BEV/CHT compared to KRAS wild-type patients. KRAS mutation was an independent predictor of shorter PFS (hazard ratio, 0.597; p = 0.011) and OS (hazard ratio, 0.645; p = 0.012) in the BEV/CHT group. G12D KRAS-mutant patients receiving BEV/CHT showed significantly shorter PFS (3.7 months versus 8.27 months in the G12/13x group; p = 0.0032) and OS (7.2 months versus 16.1 months in the G12/13x group; p = 0.0144). In this single-center, retrospective study, KRAS-mutant LADC patients receiving BEV/CHT treatment exhibited inferior PFS and OS compared to those with KRAS wild-type advanced LADC. G12D mutations may define a subset of KRAS-mutant LADC patients unsuitable for antiangiogenic therapy with BEV. MDPI 2019-10-09 /pmc/articles/PMC6827133/ /pubmed/31600989 http://dx.doi.org/10.3390/cancers11101514 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Ghimessy, Áron Kristof Gellert, Áron Schlegl, Erzsebet Hegedus, Balazs Raso, Erzsebet Barbai, Tamas Timar, Jozsef Ostoros, Gyula Megyesfalvi, Zsolt Gieszer, Balazs Moldvay, Judit Renyi-Vamos, Ferenc Lohinai, Zoltan Hoda, Mir Alireza Klikovits, Thomas Klepetko, Walter Laszlo, Viktoria Dome, Balazs KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title_full | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title_fullStr | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title_full_unstemmed | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title_short | KRAS Mutations Predict Response and Outcome in Advanced Lung Adenocarcinoma Patients Receiving First-Line Bevacizumab and Platinum-Based Chemotherapy |
title_sort | kras mutations predict response and outcome in advanced lung adenocarcinoma patients receiving first-line bevacizumab and platinum-based chemotherapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6827133/ https://www.ncbi.nlm.nih.gov/pubmed/31600989 http://dx.doi.org/10.3390/cancers11101514 |
work_keys_str_mv | AT ghimessyaronkristof krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT gellertaron krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT schleglerzsebet krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT hegedusbalazs krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT rasoerzsebet krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT barbaitamas krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT timarjozsef krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT ostorosgyula krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT megyesfalvizsolt krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT gieszerbalazs krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT moldvayjudit krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT renyivamosferenc krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT lohinaizoltan krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT hodamiralireza krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT klikovitsthomas krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT klepetkowalter krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT laszloviktoria krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy AT domebalazs krasmutationspredictresponseandoutcomeinadvancedlungadenocarcinomapatientsreceivingfirstlinebevacizumabandplatinumbasedchemotherapy |